Most Recent
Railway technology company Wavetrain Systems has asked the court to bar a competitor started by its former CEO from making allegedly false claims about its patented rail safety devices to clients.
A judge that rejected a bid by Sanofi-Aventis for an injunction blocking rival Alphapharm from listing an insulin injector pen on the PBS erred in his consideration of the harm it would face, the drug giant has told the Full Federal Court.
AMP executives are the focus of the Australian Securities and Investments Commission's investigation of the wealth management firm's fees for no service scandal, a court heard Friday.
Acciona Infrastructure and Transport for NSW are currently in settlement talks over a $1.2 billion dispute around the NSW government's ongoing light rail project in Sydney.
Pharmaceutical giant Wyeth has shot down arguments by rival Merck Sharp & Dohme that its Prevnar 13 vaccine lacked inventiveness, saying during the closing submissions of a high-stakes patent trial that up until it developed the top-selling shot scientists thought there was a "ceiling" of 11 types of pneumococcal bacteria that could be included in a single vaccine.
A judge won't defer the opt-out notice in a shareholder class action against GetSwift pending the High Court's decision on a special leave application to revive a competing class action, saying the sooner the case settles the better.
The Australian Securities and Investments Commission will likely appeal a ruling that two Westpac units did not provide personal financial advice as part of a campaign encouraging customers to roll over external superannuation accounts.
Greens senator Sarah Hanson-Young, who is suing fellow senator David Leyonhjelm for defamation, has asked a court for the costs of having her lawyers appear at a hearing for which his side failed, without explanation, to appear.
Law firms Maurice Blackburn and Phi Finney McDonald have stepped back from a proposed consolidation of their class actions against the Commonwealth Bank of Australia and want to run their own cases again, but now with "harmonised" pleadings.
Claims by Wyeth that its patented Prevnar 13 pneumococcal vaccine was inventive because other pharmaceutical giants had failed in developing similar vaccines are based on "hearsay and speculation," Merck Sharp & Dohme told the court during closing submissions in the high-stakes trial over the world's best-selling vaccine.